08/07/17 Compounding Confusion: Uncertainty Swirls in Compound Pharmacy Regulation Five years after the New England Compounding Center tragedy led the FDA to step in as a primary regulator of compounding pharmacies, uncertainties and anxieties abound. That was the thread running through a discussion led by Quarles & Brady partners Theodore... More
12/28/16 – Media Mention Theodore M. Sullivan quoted in article “Medical Device Makers Urged to Beef Up Product Cybersecurity” Below is an excerpt: Many in the device industry have urged the FDA to clarify when manufacturers need to notify the agency about software updates that seek to strengthen a product’s cybersecurity, which are constantly evolving based on new information and... More Bloomberg BNA
06/01/16 – Media Mention Theodore M. Sullivan quoted in article “FDA Moves to Help CMS With Device Coverage Decisions” Below is an excerpt: The updates the draft guidance makes to the FDA's categorization process simplifies what was a complicated procedure, Theodore Sullivan, a Washington-based attorney at Quarles & Brady LLP, told Bloomberg BNA May 31. Essentially, the device categorization process comes... More Bloomberg BNA
05/09/16 Theodore Sullivan Joins Quarles & Brady’s Health & Life Sciences Practice Group WASHINGTON, D.C. — The national law firm of Quarles & Brady LLP today announced that Theodore M. Sullivan has joined the firm's Washington, D.C. office as a partner in its Health & Life Sciences Practice Group.Sullivan counsels and advises clients... More
